MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.
Blood
; 121(20): 4115-25, 2013 May 16.
Article
in En
| MEDLINE
| ID: mdl-23532732
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Lymphoma, T-Cell, Cutaneous
/
Proto-Oncogene Proteins
/
Drug Resistance, Neoplasm
/
MAP Kinase Signaling System
/
Depsipeptides
/
Protein Kinase Inhibitors
/
Apoptosis Regulatory Proteins
/
Histone Deacetylase Inhibitors
/
Membrane Proteins
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Blood
Year:
2013
Type:
Article
Affiliation country:
United States